Bristol Myers Squibb and Hengrui Pharma Finalize $15.2 Billion Strategic Licensing Deal
US pharmaceutical giant Bristol Myers Squibb and China’s Hengrui Pharma have finalized a historic $15.2 billion strategic licensing agreement. The deal grants BMS exclusive rights to four of Hengrui’s early-stage oncology and hematology candidates outside Greater China, while Hengrui secures commercialization rights for four of BMS’s immunology drugs within the region. Additionally, the companies will co-develop five new programs. This landmark transaction highlights the growing integration of Chinese innovation into global pharmaceutical pipelines and provides BMS with critical assets to offset future patent expiries.
Editorial summary awaiting refresh
Cross-source coverage
Wire timeline
Bristol Myers Squibb and Hengrui Pharma Announce $15.2 Billion Strategic Collaboration
Bristol Myers Squibb (BMS) and Hengrui Pharma have entered into a major global strategic collaboration and licensing agreement valued at up to $15.2 billion. Announced on May 12, 2026, the partnership encompasses 13 early-stage programs across oncology, hematology, and immunology. The deal includes four assets from Hengrui, four from BMS, and five jointly developed programs. BMS will make an upfront payment of $600 million to Hengrui, with additional contingent payments scheduled for subsequent anniversaries. Under the terms, BMS secures exclusive worldwide rights to Hengrui-originated assets outside mainland China, Hong Kong, and Macau, while Hengrui retains rights to BMS-originated assets within these regions. Hengrui will lead early clinical development to accelerate proof-of-concept generation, leveraging its discovery platforms alongside BMS’s global commercialization expertise. The transaction, subject to regulatory review, is expected to close in the third quarter of 2026. This alliance aims to combine complementary scientific capabilities to address unmet medical needs and drive long-term portfolio growth for both pharmaceutical giants through shared innovation and efficient development pathways.
PharmExec articlesBMS and Hengrui Forge $15.2bn Alliance for Early-Stage Drugs
Bristol Myers Squibb (BMS) and Chinese biopharma company Hengrui Pharma have finalized a historic licensing and collaboration agreement valued at up to $15.2 billion. The deal centers on thirteen early-stage assets across oncology, haematology, and immunology. Under the terms, BMS pays $600 million upfront, with additional payments of $175 million on the first and second anniversaries. BMS secures exclusive global rights outside Greater China for four of Hengrui’s haematology candidates, while Hengrui obtains rights to four of BMS’s immunology programs within Greater China. Furthermore, the companies agreed to co-develop five innovative assets, allowing Hengrui to participate in global commercial activities for specific medicines upon approval. This strategic alliance aims to accelerate clinical learning and drive growth for BMS as it prepares for impending patent expiries of key drugs like Opdivo and Eliquis. By restocking its pipeline through this partnership and recent acquisitions, BMS seeks to mitigate biosimilar erosion and secure next-generation blockbuster therapies. The agreement represents one of the highest-value deals in pharmaceutical industry history, highlighting the increasing trend of cross-border collaborations to enhance drug development capabilities.
Pharmaceutical TechnologyBristol Myers Squibb Signs $15.2 Billion Licensing Deal with China's Hengrui Pharma
Pharmaceutical giant Bristol Myers Squibb (BMS) has entered into a significant strategic licensing agreement with Jiangsu Hengrui Pharmaceuticals, a leading Chinese biopharmaceutical company. The deal, valued at up to $15.2 billion, grants BMS exclusive rights to develop and commercialize 13 early-stage drug candidates globally, excluding China. These assets span critical therapeutic areas including oncology, hematology, and immunology, reflecting BMS's continued focus on expanding its pipeline in high-demand medical fields. Under the terms of the agreement, Hengrui will receive an upfront payment of $600 million, with the remaining value contingent upon achieving specific development, regulatory, and commercial milestones. This transaction underscores the growing trend of Western pharmaceutical companies leveraging innovation from Chinese biotech firms to bolster their drug portfolios. For Hengrui, the partnership provides substantial capital to fund further research and development while validating its scientific capabilities on a global stage. The collaboration aims to accelerate the delivery of novel therapies to patients worldwide, highlighting the increasing integration of the global pharmaceutical industry and the rising influence of Chinese innovation in drug discovery.
QuartzHengrui Pharma Signs $15.2 Billion Deal with Bristol Myers Squibb
Jiangsu Hengrui Pharmaceutical, China’s largest drug company by market capitalization, has finalized a major global collaboration and licensing agreement with US pharmaceutical giant Bristol Myers Squibb (BMS). The deal, valued at up to US$15.2 billion contingent on meeting development, regulatory, and commercial milestones, significantly boosts Hengrui's stock performance, with shares rising in both Hong Kong and Shenzhen markets. Under the agreement, BMS will provide an upfront payment of US$600 million and up to US$950 million in near-term consideration. The partnership encompasses thirteen preclinical programs, including four oncology and haematology assets from Hengrui, four immunology assets from BMS, and five novel jointly developed programmes. Hengrui will also receive tiered royalties on sales outside mainland China, Hong Kong, and Macau. This landmark transaction underscores the growing credibility of China’s innovative drug development sector on the global stage, although industry experts note that the country still faces challenges in establishing a dominant voice within the international pharmaceutical industry.
News - South China Morning PostBristol Myers Squibb Partners with Hengrui Pharma in $15.2 Billion Deal
Bristol Myers Squibb (BMS) has announced a strategic licensing agreement with China-based Hengrui Pharma, marking a significant expansion of global pharmaceutical interests into the Chinese market. The deal, valued at up to $15.2 billion including milestones, features a $600 million upfront payment from BMS to Hengrui. Under the terms, BMS acquires rights to four of Hengrui’s early-stage oncology and hematology drug candidates for markets outside mainland China, Hong Kong, and Macau. Conversely, Hengrui gains commercialization rights for four of BMS’s immunology drugs within that same region. Additionally, the two companies will collaborate on advancing five other drug programs, with Hengrui leading early clinical development efforts. This partnership highlights a growing trend where major Western pharmaceutical firms look to Chinese biotech companies for innovative early-stage medicines. The agreement covers more than a dozen programs in total, aiming to leverage Hengrui’s development capabilities and BMS’s global commercial reach. This move underscores the increasing importance of cross-border collaborations in the biopharma industry, particularly in accessing novel therapies for cancer and immune-related diseases.
STAT